Amplia Therapeutics Limited has completed its institutional offer

Amplia Therapeutics Limited (ASX: ATX) announces the successful completion of its institutional placement, a critical step in its ongoing mission to combat pancreatic cancer. This institutional component is part of a pioneering 1 for 6.45 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Amplia. It communicated this significant milestone to the ASX on 30 October 2024.As part of this comprehensive offer, new shares come with the added benefit of valuable free attaching options at an attractive rate of three options for every four new shares. These options allow shareholders to acquire additional shares at an exercise price of AU$ 0.1725, valid until 31 October 2027.

The institutional offer is set to raise approximately AU$ 9.9 million at an offer price of AU$ 0.115 per new share. This will consist of around AU$ 7.8 million from the placement, approximately AU$ 0.3 million from the director placement, and about AU$ 1.8 million from the institutional entitlement offer. This successful capital raise is a significant milestone for Amplia, providing it with the resources to advance its critical objectives in the fight against pancreatic cancer.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com